Take Control of Your T Cell Assays - Recent Publications Covering our Peptide Control Pools

Published on 30/10/2023

We have recently launched an updated version of our proprietary CEFX Ultra SuperStim Pool, namely the CEFSX Ultra SuperStim Pool. This new control pool now provides coverage for a broad range of HLA sub-types and different infectious agents including SARS-CoV-2 Spike antigens, generating specific T cell responses across different biogeographical ancestries. 

Our positive and negative control pools cover a variety of infectious diseases and human antigens allowing for reliable validation of your T cell assays. 

Moreover, take a peek at publications making use of our extensive catalog, as they exemplify the range of our control products and their applicability in immunotherapy, vaccine development, method developments, or cancer research: 

  1. Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study
    Voong et al., Journal for ImmunoTherapy of Cancer (2023) – PMID: 37793854
    Products used: CEFX Ultra SuperStim Pool MHC-II Subset, PepMix™ HIV-1 (GAG) 
  2. Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELDTM and COVAXIN® induced immunity in COVID-19 exposed Indians
    Rakshit et al., NPJ Vaccines (2023) – PMID: 37709772
    Product used: CEFT Pool 
  3. Validation of the performance and suitability of a new class of FBS optimized for use in single-cell functional assays
    Berrong et al., Journal of Immunological Methods (2023) – PMID: 36858170
    Products used: CEF Pool (extended)CEFT MHC-II PoolPepMix™ HCMVA (pp65) 
  4. Age-related Differences in Immune Reactions to SARS-CoV-2 Spike and Nucleocapsid Antigens
    Morhart et al., In Vivo (2023) – PMID: 36593041
    Products used: CEFX Ultra SuperStim PoolPepMix™ Human (Actin)
  5. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
    Friedrich et al., Cancer Cell (2023) – PMID: 36898378
    Product used: CEFT Pool
  6. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
    Palmer et al., Nature Medicine (2022) – PMID: 35970920
    Product used: CEF Pool (standard) 

Find more references 

If you have questions or want to discuss our large variety of custom peptide synthesis formats, please contact us.

Check our list of products, click and go.

Get a quote